NIH unveils clinical trial supply facility; plans service expansion

The NIH Clinical Center's Pharmaceutical Development Section is readying to cash in on a seven-year effort by moving into a new $12-million facility. The June move to the 1,115-square-meter drug-making plant marks a big change from the 743-square-meter workspace it has occupied for 50 years.

The PDS's 20 chemists, pharmacists, pharmacokineticists and technicians produce investigational treatments used in many of the hundreds of the Clinical Center's ongoing studies--about one-third of the 1,000 drugs, including placebos. Drug forms include solid oral dosage, injection, IV, ointments and creams.

NIH hosted reporters on a walk-through in late March.

The center's plans include services provided not just to on-site NIH researchers and clients but also to outside clinical investigators. The current one-shift operation is eventually expected to run 24/7.

- read the article

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)